Elizabeth Riley, MD
Hematology & Oncology · Louisville, KYNPI 1235202540
Payments from drug & device makers
Across 358 payments — averaging $2083.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$417K
- Gilead$119K
- Eli Lilly$67K
- Novartis$62K
- Seagen Inc.$53K
- Daiichi Sankyo Inc.$24K
- plus $3K from 27 others
Across 2 payments — averaging $10,325 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ichnos Glenmark Innovation Inc$21K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 137 | $417,448 |
| Gilead | 23 | $119,152 |
| Eli Lilly | 10 | $67,437 |
| Novartis | 34 | $62,447 |
| Seagen Inc. | 7 | $52,518 |
| Daiichi Sankyo Inc. | 31 | $24,322 |
| Athenex Pharmaceutical Division, LLC | 2 | $522 |
| Amgen | 28 | $417 |
| Pfizer | 13 | $225 |
| Lilly USA, LLC | 7 | $138 |
| AstraZeneca | 8 | $131 |
| Bristol Myers Squibb | 5 | $129 |
| Foundation Medicine, Inc. | 6 | $112 |
| Johnson & Johnson | 5 | $102 |
| Stemline Therapeutics Inc. | 5 | $87 |
| Puma Biotechnology, Inc. | 5 | $83 |
| Eisai Inc. | 5 | $80 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $79 |
| Coherus Oncology, Inc. | 3 | $48 |
| E.r. Squibb & Sons, L.L.C. | 3 | $45 |
| Incyte Corporation | 3 | $44 |
| Sanofi | 2 | $43 |
| Rigel Pharmaceuticals, Inc. | 2 | $33 |
| Genentech USA, Inc. | 2 | $28 |
| Pharmaessentia USA Corporation | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Agios Pharmaceuticals, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $20 |
| AbbVie | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Tersera Therapeutics LLC | 1 | $18 |
| Clovis Oncology, Inc. | 1 | $15 |
| Fennec Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$745,844 in reported general payments places this provider in the 90th percentile of 143 hematology & oncology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Louisville
- Joseph MalyLouisville$7M
- Laila AgrawalLouisville$6.3M
- Jaspreet GrewalLouisville$4.2M
- Rebecca RedmanLouisville$2.1M
- Vivek SharmaLouisville$1.9M
- Rohit KumarLouisville$1.6M
- Jeffrey HargisLouisville$1.3M
- Goetz KloeckerLouisville$1.2M
- Adam LyeLouisville$706K
- Brian DongLouisville$664K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.